TM7SF3

Across TCGA pan-cancer cohorts, TM7SF3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TM7SF3 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TM7SF3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TM7SF3 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and LSCC are the cancer types where TM7SF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.553	0.928	.011	17	view →
CCRCC	OS	Median	III,IV	0.556	0.863	.016	11	view →
LSCC	DFS	Median	II,III,IV	0.482	1.000	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TM7SF3–LUAD (DFS)

Open the LUAD breakdown →